EUVIMEDEUVIMED entdecken
Open Access

Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis

Fasiha Kanwal, Saira Khaderi, Amit G Singal, Jorge A Marrero, Sumeet K Asrani, Christopher I Amos, Aaron P Thrift, Jennifer R Kramer, Xian Yu, Yumei Cao, Michelle Luster, Abeer Al-Sarraj und 2 weitere

Clinical Gastroenterology and Hepatology · 2023

DOI: 10.1016/j.cgh.2023.04.019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Fasiha Kanwal und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Section of Health Services Research, …. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: The available risk stratification indices for hepatocellular cancer (HCC) have limited applicability. We developed and externally validated an HCC risk stratification index in U.S. cohorts of patients with cirrhosis. METHODS: We used data from 2 prospective U.S. cohorts to develop the risk index. Patients with cirrhosis were enrolled from 8 centers and followed until development of HCC, death, or December 31, 2021. We identified an optimal set of predictors with the highest discriminatory ability (C-index) for HCC. The predictors were refit using competing risk regression and its predictive performance was evaluated using the area under the receiver-operating characteristic curve (AUROC). External validation was performed in a cohort of 21,550 patients with cirrhosis seen in the U.S Veterans Affairs system between 2018 and 2019 with follow-up through 2021. RESULTS: We developed the model in 2431 patients (mean age 60 years, 31% women, 24% cured hepatitis C, 16% alcoholic liver disease, and 29% nonalcoholic fatty liver disease). The selected model had a C-index of 0.77 (95% confidence interval [CI], 0.73-0.81), and the predictors were age, sex, smoking, alcohol use, body mass index, etiology, α-fetoprotein, albumin, alanine aminotransferase, and platelet levels. The AUROCs were 0.75 (95% CI, 0.65-0.85) at 1 year and 0.77 (95% CI, 0.71-0.83) at 2 years, and the model was well calibrated. In the external validation cohort, the AUROC at 2 years was 0.70 with excellent calibration. CONCLUSION: The risk index, including objective and routinely available risk factors, can differentiate patients with cirrhosis who will develop HCC and help guide discussions regarding HCC surveillance and prevention. Future studies are needed for additional external validation and refinement of risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHumansFemaleMiddle AgedMaleProspective StudiesLiver CirrhosisRisk FactorsRisk Assessment

Stichwörter der Autor:innen

Liver CancerPersonalizedPredictionValidation

Autor:innen und Institutionen

  • Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas; VA…
  • Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Division of Digestive and Liver Diseases, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
  • Division of Gastroenterology, Department of Medicine, Baylor University Medical Center, Dallas, Texas.
  • Section of Epidemiology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas; VA HSR&D Center for Innovatio ns in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medica…

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • National Cancer Institute
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Cancer Prevention and Research Institute of Texas
  • Veterans Administration Medical Center, Yale School of Medicine

Zitieren

APA

Kanwal, F., Khaderi, S., Singal, A. G., Marrero, J. A., Asrani, S. K., Amos, C. I., Thrift, A. P., Kramer, J. R., Yu, X., Cao, Y., Luster, M., Al-Sarraj, A., Ning, J., & El-Serag, H. B. (2023). Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.04.019

Vancouver

Kanwal F, Khaderi S, Singal AG, Marrero JA, Asrani SK, Amos CI, et al. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.04.019

BibTeX
@article{Kanwal2023,
  author = {Kanwal, Fasiha and Khaderi, Saira and Singal, Amit G and Marrero, Jorge A and Asrani, Sumeet K and Amos, Christopher I and Thrift, Aaron P and Kramer, Jennifer R and Yu, Xian and Cao, Yumei and Luster, Michelle and Al-Sarraj, Abeer and Ning, Jing and El-Serag, Hashem B},
  title = {Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1016/j.cgh.2023.04.019}
}
Kostenlos starten →